Synageva Biopharma (GEVA) Misses Q1 EPS by 5c; Names New COO
Tweet Send to a Friend
Synageva Biopharma (NASDAQ: GEVA) reported Q1 EPS of ($0.81), $0.05 worse than the analyst estimate of ($0.76). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
